| Assessment Status | Assessment process complete |
| HTA ID | 19039 |
| Drug | Liraglutide |
| Brand | Saxenda® |
| Indication | As an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial body mass index (BMI) of ≥30kg/m2 (obese), or ≥27kg/m2 to <30kg/m2 (overweight) in the presence of at least one weight-related comorbidity such as dysglycaemia (pre-diabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia or obstructive sleep apnoea. The Applicant is seeking reimbursement in a subgroup of the licensed population, that is, as an adjunct to a reduced calorie diet and increased physical activity for weight management in adult patients with an initial body mass index of ≥35kg/m2 with pre-diabetes and high risk of cardiovascular disease. |
| Assessment Process | |
| Rapid review commissioned | 18/09/2019 |
| Rapid review completed | 24/10/2019 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of liraglutide (Saxenda®) compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE | 29/10/2019 |
| Pre-submission consultation with Applicant | 12/11/2019 |
| Full submission received from Applicant | 08/06/2020 |
| Preliminary review sent to Applicant | 21/08/2020 |
| NCPE assessment re-commenced | 23/10/2020 |
| Follow-up to preliminary review sent to Applicant | 30/11/2020 |
| NCPE assessment re-commenced | 08/12/2020 |
| Factual accuracy sent to applicant | 15/01/2021 |
| NCPE assessment re-commenced | 22/01/2021 |
| NCPE assessment completed | 09/02/2021 |
| NCPE assessment outcome | The NCPE recommends that liraglutide 3mg (Saxenda®) not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatments*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
